Difference in vasoconstrictors: oxymetazoline vs. brimonidine
Objective Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. Methods and materials Phase I...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1639606 |
| _version_ | 1797683651454959616 |
|---|---|
| author | Nwanneka Okwundu Abigail Cline Steven R. Feldman |
| author_facet | Nwanneka Okwundu Abigail Cline Steven R. Feldman |
| author_sort | Nwanneka Okwundu |
| collection | DOAJ |
| description | Objective Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. Methods and materials Phase II and phase III clinical studies evaluating oxymetazoline and brimonidine were assessed to compare their efficacy and safety. Results In their respective phase III trials, both oxymetazoline and brimonidine met the primary efficacy outcome of having at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment (SSA) Scales compared to the vehicle control. Treatment related adverse events of oxymetazoline and brimonidine are most often mild and localized. Conclusions Topical oxymetazoline and brimonidine are effective for the management of persistent facial erythema associated with rosacea with a few mild and localized adverse effects. Further long-term research is imperative to further understand their long-term effects. |
| first_indexed | 2024-03-12T00:17:39Z |
| format | Article |
| id | doaj.art-0a821b6df4cc4b1bb448846a7d3fc3ca |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:39Z |
| publishDate | 2021-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-0a821b6df4cc4b1bb448846a7d3fc3ca2023-09-15T14:23:03ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-02-0132213714310.1080/09546634.2019.16396061639606Difference in vasoconstrictors: oxymetazoline vs. brimonidineNwanneka Okwundu0Abigail Cline1Steven R. Feldman2Department of Dermatology, Center for Dermatology Research, Wake Forest School of MedicineDepartment of Dermatology, Center for Dermatology Research, Wake Forest School of MedicineDepartment of Dermatology, Center for Dermatology Research, Wake Forest School of MedicineObjective Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. Methods and materials Phase II and phase III clinical studies evaluating oxymetazoline and brimonidine were assessed to compare their efficacy and safety. Results In their respective phase III trials, both oxymetazoline and brimonidine met the primary efficacy outcome of having at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment (SSA) Scales compared to the vehicle control. Treatment related adverse events of oxymetazoline and brimonidine are most often mild and localized. Conclusions Topical oxymetazoline and brimonidine are effective for the management of persistent facial erythema associated with rosacea with a few mild and localized adverse effects. Further long-term research is imperative to further understand their long-term effects.http://dx.doi.org/10.1080/09546634.2019.1639606adrenergicrosaceaerythemabrimonidineoxymetazoline |
| spellingShingle | Nwanneka Okwundu Abigail Cline Steven R. Feldman Difference in vasoconstrictors: oxymetazoline vs. brimonidine Journal of Dermatological Treatment adrenergic rosacea erythema brimonidine oxymetazoline |
| title | Difference in vasoconstrictors: oxymetazoline vs. brimonidine |
| title_full | Difference in vasoconstrictors: oxymetazoline vs. brimonidine |
| title_fullStr | Difference in vasoconstrictors: oxymetazoline vs. brimonidine |
| title_full_unstemmed | Difference in vasoconstrictors: oxymetazoline vs. brimonidine |
| title_short | Difference in vasoconstrictors: oxymetazoline vs. brimonidine |
| title_sort | difference in vasoconstrictors oxymetazoline vs brimonidine |
| topic | adrenergic rosacea erythema brimonidine oxymetazoline |
| url | http://dx.doi.org/10.1080/09546634.2019.1639606 |
| work_keys_str_mv | AT nwannekaokwundu differenceinvasoconstrictorsoxymetazolinevsbrimonidine AT abigailcline differenceinvasoconstrictorsoxymetazolinevsbrimonidine AT stevenrfeldman differenceinvasoconstrictorsoxymetazolinevsbrimonidine |